Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-079 manufacturers

Filters

1 products found

pp-079

Nasal spray

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
Comments
Indication: Prevention and mitigation of respiratory viral infections, including virus-triggered exacerbations in chronic respiratory diseases; intended for use in vulnerable populations and as a broad-spectrum antiviral preparedness measure. Clinical stage: Phase 1 completed with reported topline data; progressing toward Phase 2 clinical development. Modality: mRNA therapeutic (lipid nanoparticle–formulated mRNA) Mechanism / Target: Intranasal delivery of mRNA encoding interferon lambda (IFN-λ), activating local innate antiviral pathways at respiratory mucosal surfaces. Route / form: Intranasal spray Differentiation: First-in-class mucosal innate-immune mRNA therapy enabling broad antiviral protection independent of viral strain; positioned to address unmet needs in chronic respiratory disease exacerbations and pandemic-readiness applications.
Manufacturer #38619

A clinical-stage biotechnology firm pioneering next-generation mRNA therapeutics and vaccines using proprietary RNA and delivery platform technologies. It advances innovative respiratory antiviral and protein-replacement candidates through clinical development with global partnering ambitions. The organization focuses on addressing unmet needs in virus-associated respiratory diseases and beyond.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.